elironrasib

Elironrasib is a small molecule inhibitor developed as a selective RAS(ON) G12C inhibitor, targeting the KRAS G12C mutation found in various cancers, most notably non-small cell lung cancer (NSCLC). It is designed to irreversibly inhibit the active (ON) state of mutant KRAS G12C protein, thereby blocking downstream signaling pathways that drive tumor growth and survival. Elironrasib has demonstrated encouraging antitumor activity and an acceptable safety profile in clinical trials for NSCLC patients previously treated with immunotherapy and chemotherapy. In monotherapy studies at 200 mg twice daily, it achieved an objective response rate (ORR) of 56% and a disease control rate (DCR) of 94%, with predominantly low-grade treatment-related adverse events. Combination strategies are also being explored, including pairing elironrasib with immune checkpoint inhibitors like pembrolizumab or other RAS pathway inhibitors such as daraxonrasib[6][8].

Other names

elironrasib